Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.43 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1466714 | 0.85 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2GAAMAPTHTT | |
| SCHEMBL1465884 | 0.84 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2GAAMAPTHTT | |
| SCHEMBL3969958 | 0.84 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2GAAHTTLMNA | |
| SCHEMBL8294904 | 0.84 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2GAARAB9ANPC1 | |
| SCHEMBL6766311 | 0.84 | TRIM24 (0.51) | ALDH1A1SMN1; SMN2GAARAB9ANPC1 | |
| SCHEMBL3111830 | 0.78 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2GAARAB9ANPC1 | |
| SCHEMBL5552951 | 0.76 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2GAARAB9ANPC1 | |
| SCHEMBL14365405 | 0.76 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2GAARAB9ANPC1 | |
| SCHEMBL1255150 | 0.75 | TRIM24 (0.52) | ALDH1A1RAB9ANPC1LMNATRIM24 | |
| SCHEMBL13990851 | 0.75 | RAB9A (0.60) | ALDH1A1SMN1; SMN2GAARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101123959-A | Aryl, heteroaryl and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions thereof for the treatment of human diseases | RENOVIS INC (US) | 2008-02-13 | — | — | CN | disclosed |
| US-20070275932-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | RENOVIS, INC. | 2007-11-29 | — | — | US | disclosed |
| EP-1660011-A2 | ARYL, HETEROAROMATIC AND BICYCLIC ARYL NITRONE COMPOUNDS, PRODRUGS AND PHARMACEUTICAL COMPOSITIONS OF THE SAME TO TREAT HUMAN DISORDERS | Renovis, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050059638-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | RENOVIS, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2005016272-A2 | ARYL, HETEROAROMATIC AND BICYCLIC ARYL NITRONE COMPOUNDS, PRODRUGS AND PHARMACEUTICAL COMPOSITIONS OF THE SAME TO TREAT HUMAN DISORDERS | RENOVIS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20040192680-A1 | Novel amides that activate soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-09-30 | — | — | US | disclosed |
| WO-2004060859-A2 | NOVEL AMIDES THAT ACTIVATE SOLUBLE GUANYLATE CYCLASE | ABBOTT LABORATORIES (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20040121994-A1 | Novel amides that activate soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275932-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | AHR, NAT1, ARNT | ALDH1A1 487/4885SMN1; SMN2 155/4885GAA 426/4885 |
| US-20050059638-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | AHR, NAT1, ARNT | ALDH1A1 487/4885SMN1; SMN2 155/4885GAA 426/4885 |
| US-20040121994-A1 | Novel amides that activate soluble guanylate cyclase | GUCY1A1, GUCY1B1, GUCY1A2 | ALDH1A1 510/4885SMN1; SMN2 710/4885GAA 1898/4885 |
| US-20040192680-A1 | Novel amides that activate soluble guanylate cyclase | GUCY1A1, GUCY1B1, GUCY1A2 | ALDH1A1 510/4885SMN1; SMN2 710/4885GAA 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.